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Abstract
NOTCH1 pathway activation contributes to the pathogenesis of over 60% of T-cell acute
lymphoblastic leukemia (T-ALL). While Notch is thought to exert the majority of its effects
through transcriptional activation of Myc, it also likely has independent roles in T-ALL
malignancy. Here, we utilized a zebrafish transgenic model of T-ALL, where Notch does not
induce Myc transcription, to identify a novel Notch gene expression signature that is also found in
human T-ALL and is regulated independently of Myc. Cross-species microarray comparisons
between zebrafish and mammalian disease identified a common T-ALL gene signature, suggesting
that conserved genetic pathways underlie T-ALL development. Functionally, Notch expression
induced a significant expansion of pre-leukemic clones; however, a majority of these clones were
not fully transformed and could not induce leukemia when transplanted into recipient animals.
Limiting-dilution cell transplantation revealed that Notch signaling does not increase the overall
frequency of leukemia-propagating cells (LPCs), either alone or in collaboration with Myc. Taken
together, these data indicate that a primary role of Notch signaling in T-ALL is to expand a
population of pre-malignant thymocytes, of which a subset acquire the necessary mutations to
become fully transformed LPCs.
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tIntroduction
T-cell acute lymphoblastic leukemia is an aggressive malignancy of thymocytes. Despite
improved therapies, patients with relapsed disease have a 5-year survival rate of <30% (1).
T-ALL is thought to arise from a subset of cells known as leukemia-propagating cells
(LPCs), which are rare cells that have the ability to reform the leukemia from a single cell
(2,3), and are thus believed to be critical for inducing relapse. Recent studies have
demonstrated that clonal evolution frequently occurs in relapsed T-ALL, resulting in new
genomic changes within transformed cells. These genetic lesions were selected for at relapse
and likely result in a more aggressive malignancy, due in part to their ability to increase the
relative frequency of LPCs within the leukemia and thus enhance LPC activity (4,5). Genes
frequently mutated at relapse include PTEN, FBXW7, MYC, and NOTCH1; however, it is
currently unknown whether these genes enhance LPC frequency and/or promote LPC
activity to drive relapse formation.
NOTCH1 is the most commonly mutated oncogene in T-ALL, with >60% of T-ALL
patients harboring activating NOTCH1 mutations that confer ligand independent activation
or increased stability of the Notch intra-cellular domain (NotchICD) (6,7). Transgenic mouse
experiments confirmed that NotchICD initiates a highly penetrant T-ALL when introduced
into bone marrow-derived cells and elicits transformation by acting as a transcription factor
(8,9). Activating Notch mutations spontaneously occur in several mouse models of T-ALL
and exhibit similar mutation spectra as human disease (10–12), suggesting a central role for
Notch in T-ALL malignancy. Currently, there are conflicting reports regarding the role of
Notch signaling in LPC development and function. Recent studies have suggested that
Notch signaling plays a role in LPC maintenance, in that Notch activation in primary human
T-ALL cells is critical for their ability to serially xenograft in mice (2) and inhibition of
Notch signaling in a mouse model of T-ALL also significantly reduced leukemia
development when transplanted into syngeneic recipients (13). However, others have
indicated that Notch signaling is not sufficient to induce LPC formation (14) or long-term
repopulating potential in normal thymocytes (15). To date, a role for NOTCH in regulating
leukemia-propagating cell frequency and function remains controversial.
Understanding the precise role of Notch in LPC biology is confounded by its transcriptional
activation of the Myc oncogene in mammalian T-ALL (16–18). Notch was found to promote
T-ALL proliferation in human cell lines exclusively through Myc activation (18) and
Emerging evidence suggests that Myc can play a critical role in the maintenance of normal
tissue stem cells (19). Whether the effects of Notch on LPCs are driven by the Notch/Myc
axis is currently unknown. Importantly, Notch also collaborates with Myc to enhance T-
ALL development in transgenic mouse models, and synergy between Myc and Notch was
identified in retroviral based screens in T-cell malignancy (17,20,21). These latter results
would not be expected if the Notch/Myc axis was strictly linear. In normal tissues, where
Notch does not necessarily induce Myc expression, Notch signaling can promote stem cell
survival and self-renewal (22). Taken together, it is likely that NOTCH has other important
roles in T-ALL malignancy, apart from Myc induction.
We have utilized the Myc- (23) and NotchICD-induced (24) zebrafish T-ALL models to
better understand the function of each of these transcription factors in T-ALL development
and LPC function. These models are uniquely well-suited to this type of study, in that Notch
does not transcriptionally activate myc in zebrafish T-ALL (24), and notch1a and notch1b
are not mutationally activated in Myc-induced T-ALL, suggesting that Notch and Myc exert
independent and non-overlapping roles in regulating diverse oncogenic T-ALL pathways.
Our microarray comparisons indicate that zebrafish T-ALL shares molecular similarities to
both human and mouse disease, and revealed a novel Notch gene signature that is regulated
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tindependently of Myc. Functionally, we found that Notch collaborates with Myc to
significantly decrease time to leukemia onset without affecting overall proliferation rates or
apoptosis. Clonal analysis of these primary T-ALL cells demonstrates that Notch signaling
results in a significant expansion of a pool of T cell clones. However, a majority of these
clones are not fully transformed and could not engraft disease into syngeneic recipient
animals. Additionally, by utilizing limiting-dilution cell transplantation of leukemic cells
into over 1,200 recipient animals, we found that Notch signaling did not increase the overall
frequency of LPCs in T-ALL. Together, these data suggest that mutational activation of
Notch likely acts as a primary initiating event in T-ALL through expansion of a pre-
malignant pool of T cell clones, a subset of which acquire additional mutations to become
fully transformed LPCs.
Methods
Stable transgenic zebrafish that develop T-ALL
rag2-GFP (25) and rag2-NOTCH(ICD)-EGFP (human Notch expressing) (24) zebrafish lines
have been described. Stable transgenic rag2-EGFP-Myc (murine Myc) zebrafish were re-
created using meganuclease transgenic technology. Transgenic fish were monitored for
disease onset beginning at 21 days post-fertilization (dpf) and every 7 days thereafter.
Thymic hyperplasia was defined by a three-fold increase in thymus size, and lymphoma by
the local expansion of GFP-positive lymphoblasts outside the thymus. Leukemia was
defined as >50% of the animal being overtaken by GFP-positive lymphoblasts, established
previously as a robust surrogate for infiltration of lymphocytes into the marrow (26).
Representative animals at various stages of disease progression are shown in Supplemental
Figure 1. Kaplan-Meier analyses were completed using the SAS program and results are
presented using the Log-rank (Mantel-Cox) test.
Generation of mosaic transgenic animals that develop T-ALL
Transgenes were prepared as previously described (27). 40 ng/µL rag2-GFP was mixed with
20 ng/µL of either rag2-Myc (murine Myc) or rag2-notch1aICD (zebrafish Notch), and for
injections with all 3 constructs, 20 ng/µL of each plasmid were used. DNA was
microinjected into one-cell stage CG1 embryos. Animals with GFP-positive thymi at day 21
dpf were monitored for disease onset every 7 days. GFP-negative fish were re-screened
every 30 days for 6 months to ensure that diseased animals were not missed in our analysis
and to verify that T-ALL did not develop in animals that failed to have GFP-labeled
thymocytes at day 21 dpf.
Leukemia cell morphology, cell cycle, and apoptosis analysis
Cytospins and FACS analysis of kidney marrow and spleen were completed as described
(23), with propidium iodide was used to exclude dead cells. For cell cycle and apoptosis
analysis, unsorted cells were isolated from leukemic fish and analyzed for DNA synthesis
using Click IT EDU Alexa Fluor 647 (Invitrogen) according to the manufacturer’s protocol.
Of note, cells were incubated with EDU for 30’, then fixed in 4% paraformaldehyde before
Alexa Fluor conjugation. Propidium iodide was used as a counter-stain. Unsorted cells were
also stained with Annexin V Alexa Fluor 647 (Invitrogen) in the presence of propidium
iodide, according to manufacturer’s protocol to quantify apoptotic cells. For all experiments,
unsorted normal thymocytes were collected by dissecting GFP-positive thymus from 45d
rag2-GFP animals, and whole blood was collected from 45d CG1-strain zebrafish for use as
controls.
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T-cell receptor (TCR) recombination has been used extensively to follow minimal residual
disease in human T-ALL and is a robust way to assess clonality (28,29). We created an
analogous assay to detect each of the 102 individual TCRβ rearrangements in zebrafish
(Supplemental Figure 2). RNA was extracted from FACS sorted T-ALL cells, made into
cDNA, and PCR was performed utilizing each Vβ and Cβ primer (Supplemental Table 1). A
semi-nested PCR was completed using 1 µL of the PCR product and resolved on a 2%
agarose gel.
Cell transplantation
GFP-positive cells from T-ALL, lymphoma and hyperplasia were isolated and transplanted
as previously described (30,31). Briefly, tumor-bearing fish were macerated in 5%FBS
+0.9XPBS, cells were strained through 40 µm nylon mesh (BD Falcon) and stained with PI
before FACS. GFP+/PI− cells (≥95% purity, >98% viability) were sorted at the appropriate
number into wells of a 96-well plate containing 50 µL 5%FBS+0.9XPBS plus 3×104 whole
blood cells isolated from CG1-strain zebrafish. Cells were centrifuged, cell pellets re-
suspended in 5 µL 5%FBS+0.9XPBS and transplanted by intra-peritoneal injection into >60
day old CG1-strain recipients. Fish were monitored for T-ALL growth for up to 120 days.
Leukemia-propagating cell frequency was calculated using the Extreme Limiting Dilution
Analysis software (http://bioinf.wehi.edu.au/software/elda/) (32).
Microarray Analyses
RNA was extracted from 3×105 GFP-positive leukemia cells (FACS isolated as above) and
normal thymocytes from 45d rag2-GFP animals, (RNeasy Plus Micro kit, Qiagen),
amplified, and labeled with Cy3. Reference control RNA from total CG1-strain fish (2 males
and 2 females) was labeled with Cy5. Samples were hybridized together onto the Zebrafish
44K Agilent microarray, scanned, and probes identified at various log-fold change
differences with p<0.01 using a standard two-tailed T-test. Zebrafish Agilent probe IDs were
mapped to their human homologues using the Beagle Genetic Analysis Software Package
(http://chgr.mgh.harvard.edu/genomesrus/index.php).
Gene set enrichment analysis (GSEA) was completed essentially described (33) using
microarray data sets of interest including: GSE19499, a study comparing TLX-1 induced
murine T-ALL to several other genetic T-ALL models in mouse (34) and GSE7050, a study
comparing a β-catenin driven mouse T-ALL model (CD4Cre-Ctnnbex3) to thymocytes from
LCKCre control mice (35), as well as GSE13425 and GSE13351 where 190 human
diagnosis ALL samples were used to develop a classifier between T-ALL and B-ALL, then
confirmed in an independent cohort of 107 patient samples (36). The murine data sets were
combined using a trimmed mean followed by quantile normalization to create a merged
GCT file. GSEA significance was defined by a p<0.05 and false discovery rate (FDR)≤
0.25.
Real-time RT-PCR
RNA was extracted from 3×105 FACS sorted zebrafish T-ALL cells and from human T-
ALL cells using an RNeasy Mini kit with on-column DNAse treatment (Qiagen). Total
RNA was reverse transcribed (Reverse Transciption kit, Applied Biosystems), and real-time
PCR was performed using Power Sybr 2X Master Mix (Invitrogen, primers available in
Supplemental Table 2). Data were normalized to ef1α expression; fold-change was
calculated using the 2−ΔΔCt method.
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Notch collaborates with Myc to enhance zebrafish T-ALL progression
Notch collaborates with Myc to enhance leukemia onset in mouse models of T-ALL. To
confirm that Notch also synergizes with Myc in zebrafish T-ALL, heterozygous stable
transgenic rag2-EGFP-Myc fish were crossed with rag2-NOTCH(ICD)-EGFP animals. Each
of these lines were also crossed with rag2-GFP animals as a control (AB* strain, n=123
double transgenic fish, n=63 Myc and n=47 NOTCH(ICD). Double transgenic animals
developed thymic hyperplasia 10 days faster than those that expressed Myc alone
(p<0.0001, Log-rank test), which progressed rapidly to lymphoma (Figure 1A–B). The Myc
+NOTCH(ICD) double transgenic animals had an accelerated time to T-ALL onset (40.9±9.2
days) compared to Myc expressing zebrafish (46.2±9.3 days, p=0.0067). As previously
reported, the stable transgenic rag2-NOTCH(ICD)-GFP transgenic animals did not develop
disease within 6 months of life (24).
While stable transgenic approaches demonstrated a synergy of Myc and NOTCH(ICD) at
inducing T-ALL in zebrafish, these experiments required the generation of stable transgenic
lines that are difficult to maintain due to their early T-ALL onset (25). Our laboratory has
successfully used mosaic transgenic approaches to create zebrafish models of T-ALL, where
up to three transgenic constructs can be co-expressed within developing thymocytes that
eventually give rise leukemia (33,37). Specifically, linearized DNA constructs are co-
injected into one-cell stage embryos; a subset of the resulting mosaic animals incorporate
transgenes into thymocytes, leading to transgene co-expression within T cells and
subsequently the leukemia. Importantly, unlike stable transgenic approaches that drive high
transgene expression within all thymocytes, only a small subset of thymocyte precursor cells
integrate the transgene and express Myc in mosaic transgenic zebrafish. Given that a
majority of genetic mutations are acquired somatically and sporadically in human T-ALL,
we believe that use of mosaic transgenic approaches likely more accurately recapitulates
what is observed in human cancer.
To assess if mosaic transgenesis could be used to identify collaborating events in T-ALL,
one-cell stage CG1-strain, syngeneic embryos were microinjected with 1) rag2-mouseMyc
+rag2-GFP, 2) rag2-zebrafish notch1a(ICD)+rag2-GFP or 3) rag2-Myc+rag2-
notch1a(ICD)+rag2-GFP. Mosaic animals were assessed for the development of GFP-positive
thymi at 21 dpf and subsequently followed for time to T-ALL onset. Mosaic transgenic
animals that co-expressed Myc and notch1a(ICD) (n=27) exhibited significantly shortened
time to thymic hyperplasia compared to those expressing Myc (n=32, p<0.0001) or
notch1a(ICD) alone (n=18, p<0.0001). Lymphoma arose within 29.3±9.2 days in transgenic
Myc+notch1a(ICD) animals, compared to 42.9±13.2 days in Myc expressing animals
(p<0.0001). Myc+notch1a(ICD) zebrafish also developed leukemia 20 days earlier than
animals that expressed Myc alone (45.5±14.4 days, compared to 65.6±15.1 days, p=0.0002,
Figure 1A, 1C). Only 50% of animals that expressed notch1a(ICD) developed leukemia, with
an average latency of >6 months. By contrast, all rag2-Myc+rag2-GFP mosaic animals that
had GFP-labeled thymi developed leukemia (n=32 of 32). Zebrafish that did not have GFP-
positive thymi by 21 dpf never developed GFP-labeled thymocytes or T-ALL later in life
(n=362).Strikingly, mosaic transgenic zebrafish (CG1 strain) displayed a longer latency to
Myc-induced T-ALL than the stable transgenic lines (AB strain), which may be attributed to
differences in the genetic backgrounds of the animals used in each study. Despite this, our
experiments demonstrate that Myc and Notch(ICD) collaborate to induce T-ALL and
highlight that our mosaic transgenic approach is a robust methodology to identify
modulators of T-ALL progression. Subsequent analyses focused exclusively on T-ALL that
developed in mosaic transgenic animals.
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GFP-labeled T-ALL arose from the thymus of mosaic transgenic animals and shared typical
lymphoblast morphology without shape or size differences across transgenic strains (Figure
2A). Leukemias expressed high levels of each transgene (Supplemental Figure 3) and T cell
specific genes, but not the B cell specific gene IgM (Figure 2B). The expression of cd4, cd8,
rag2 and the presence of Tcr-beta rearrangements suggested that the T-ALL blast cells were
arrested at the cortical thymocyte stage, irrespective of genotype. FACS demonstrated >75%
lymphocyte infiltration into the kidney and spleen of animals with GFP-positive T-ALL
spreading over >50% of the body (n=3, Figure 2C, Supplemental Figure 4), validating whole
body imaging as a robust marker for leukemia onset and growth, as previously reported (25).
Taken together, our results are consistent with previous reports that Myc and Notch-induced
T-ALL arises from T-cells confined to the thymus of zebrafish (24,25).
Previous work utilizing the stable rag2-NOTCHICD-EGFP line demonstrated that
NOTCHICD does not induce myc expression in zebrafish22. Similarly, notch1a(ICD) did not
induce the expression of myc or its related family members in mosaic transgenic zebrafish
(Figure 2D–E, Supplemental Figure 5). In human T-ALL, common “hot-spot” mutations
found in NOTCH exons 26, 27 and 34 result in ligand-independent NOTCH activation (7).
Analysis of these same sites in genomic DNA isolated from 16 Myc-induced T-ALL
revealed that notch1a and notch1b were not mutationally activated in zebrafish T-ALL,
suggesting that notch mutations are not selected in Myc-induced T-ALL. Thus, the zebrafish
Myc and notch1a(ICD)-induced T-ALL models therefore provide a unique opportunity to
directly assess the function of Notch signaling in T-ALL apart from its role in Myc
induction.
Zebrafish T-ALL is molecularly similar to mouse and human disease
To validate the relevance of the zebrafish T-ALL model and to assess if common gene
programs are found in T-ALL across species, microarray gene expression profiling and
cross-species comparisons were completed between zebrafish, mouse, and human T-ALL.
Up- and down-regulated gene signatures were identified by comparing FACS sorted GFP-
positive zebrafish T-ALL cells (n=15) to rag2-GFP thymocytes. Gene sets were identified at
various fold change levels and compared to mouse T-ALL normalized to thymocytes using
Gene Set Enrichment Analysis (GSEA). Analysis at multiple fold change cut-offs ensured
that GSEA significance was not due to the arbitrary creation of the gene list. The zebrafish
up- and down-regulated gene sets were significantly associated with murine T-ALL at each
of the fold changes examined (p=0.004, Table 1, Supplemental Figure 6, GSEA results at
the 3-fold change cut-off listed in Supplemental Table 3 and 4) but were not specifically
associated with any transgenic mouse T-ALL model (38), indicating that zebrafish and
mouse T-ALL share common molecular pathway regulation, irrespective of initiating
oncogene. The up- and down-regulated gene sets found in zebrafish T-ALL were also
significantly associated with human T-ALL (p<0.001), but not precursor B-ALL (Table 1,
GSEA results at the 3-fold change cut off are shown in Supplemental Table 5 and 6),
confirming that zebrafish, mouse, and human T-ALL share common molecular pathway
activation. Taken together, our results suggest common molecular pathways are utilized in
T-ALL development that are highly conserved across species.
Identification of novel Notch target genes in T-ALL
The Notch/Myc axis is critical for T-ALL progression in mammals, and while Notch and
Myc may co-regulate gene expression in some instances (16), Notch likely transcriptionally
activates many Myc-independent target genes. To identify novel Notch-associated and Myc-
associated gene signatures, the following comparisons were completed on GFP-labeled
FACS sorted cells: 1) Single mosaic transgenic Myc-expressing T-ALL cells to normal
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tthymocytes isolated from 45-day-old rag2-GFP transgenic animals (Myc signature), 2) Myc
+ notch1a(ICD)-expressing T-ALL to Myc-expressing T-ALL, and 3) single mosaic
transgenic notch1a(ICD)-induced T-ALL to Myc-expressing T-ALL. The latter two
comparisons were combined to identify up and down-regulated genes that were specifically
associated with Notch status (the Notch signature) and were independent of Myc expression
(Figure 3A, Supplemental Table 7). At the three-fold change cut off, the Notch signature had
171 up-regulated genes (387 probes, Supplemental Table 8) and the Myc signature
comprised 280 up-regulated genes (523 probes, Supplemental Table 9). Importantly, only
one common gene was shared between these signatures (ankh), suggesting that our gene
expression analysis identified unique gene lists that were independently regulated by Myc or
notch1a(ICD). Realtime RT-PCR of the primary Myc, Myc+ notch1a(ICD) and notch1a(ICD)
expressing T-ALL confirmed that microarray target genes were regulated exclusively by
notch1a(ICD) (Supplemental Figure 7), and subsequent analysis of human T-ALL cell lines
treated with NOTCH or MYC inhibitors showed that a subset of genes identified in our
analysis were bone fide NOTCH targets, regulated independently of MYC, including IL7R,
BCL2, MEIS1, HES1, and MYB (Supplemental Figure 8). Finally, the Myc and Notch
specific gene signatures showed little overlap with previously identified NOTCH target
genes in human T-ALL (Supplemental Figure 9), suggesting that cross-species microarray
comparisons provide a powerful model to uncover novel genes associated with oncogene
status.
Given that NOTCH regulates transcriptional expression of MYC in human T-ALL, we
expected that both the zebrafish Myc and Notch signature genes should be coordinately
regulated in human disease. GSEA analysis was performed using our up-regulated Notch
and Myc genes sets and each was assessed for concordant regulation in NOTCH-dependent
human T-ALL cell lines that were treated with DMSO (control) or the stapled peptide
inhibitor of Notch, SAMH1 (39). DMSO treated cells would presumably have higher Notch
activity than cells treated with SAMHI. The zebrafish Myc and Notch gene signatures were
significantly up-regulated in control DMSO treated cells, but not cells treated with the Notch
inhibitor (Figure 3B, p<0.001). To verify that the zebrafish Notch signature is regulated
independent of Myc, each was assessed for concordant regulation in comparing 1) human
mammary epithelial cells transduced with either Myc or one of several other oncogenes to
GFP-transduced control cells (40), 2) Eμ-Myc induced murine B-cell lymphoma compared
to normal lymphnode (41), and 3) XBP1-induced murine multiple myeloma to B-cells (42).
The zebrafish Notch signature was not detected in the Myc or other oncogene transduced
HMECs or Eμ-Myc induced B-cell lymphoma (Figure 3B) while the zebrafish Myc
signature was significantly associated with Myc status in these cells (Figure 3B, p<0.001),
but not HMECs transduced with other oncogenes (Supplemental Table 10). Neither gene
signature was concordantly regulated in XBP1-induced multiple myeloma, indicating that
these signatures were not simply identifying a lymphocyte-specific gene signature. GSEA
analysis was also completed at various fold change cut-offs to demonstrate that the results
were not biased by arbitrary gene list selection (Supplemental Table 10). In total, the non-
overlapping Myc and Notch gene expression signatures identified in zebrafish T-ALL
validate our choice of the this model to better define the role of Notch signaling in T-ALL
development and LPC function.
Effects of Notch activity on T-ALL proliferation or apoptosis
To understand the effects of Notch signaling in T-ALL progression, zebrafish T-ALL were
analyzed for effects on cell cycle and proliferation. EDU cell cycle analysis indicated that
primary Myc+notch1a(ICD) T-ALL contained a slightly higher percentage of cells in S-phase
than Myc primary leukemias (p=0.004, Figure 4A). However, AnnexinV staining revealed
that Myc+notch1a(ICD) primary T-ALL cells were more apoptotic than Myc-induced
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tleukemias (p=0.002, Figure 4B). The higher level of apoptosis found in Myc+notch1a(ICD)
primary T-ALL was unexpected, but was not significantly different than the apoptosis
occurring in normal T cells (p=0.438). Normal thymocytes undergo extensive proliferation
and apoptosis during their development and differentiation; Myc+notch1a(ICD) primary T-
ALL cells appear to undergo similar cellular turnover, suggesting that these leukemias share
characteristics of normal, immature T cells. Interestingly, following tumor re-initiation in
recipient animals, there was no significant difference in proliferation or apoptosis between
any of the T-ALL groups (p=0.30), suggesting that notch1a(ICD) expression does not
augment proliferation rates or alter apoptosis in fully transformed T-ALL cells.
Notch signaling expands a pre-malignant pool of clones within the primary T-ALL
In T-ALL development, normal T cells undergo clonal expansion, and a subset of these cells
acquire the necessary mutations to become LPCs over time (43). We wanted to determine
whether Notch and/or Myc plays a role in this clonal expansion. Primary GFP-labeled T-
ALL cells were isolated by FACS and transplanted at 2.5×105 cells into CG1-strain,
syngeneic recipient animals. T-ALL cells were re-isolated from the transplant animals after
leukemia development (>45 days), and purified by FACS. The primary and transplanted
leukemias were then assessed for expression of TCRβ transcript variants to identify the
number of expanded T cell subclones contained within each T-ALL. Primary and
transplanted Myc-induced T-ALL contained 2.1±1.1 subclones, with each clone from the
primary T-ALL being detected in transplant animals (Figure 5A). Myc-induced hyperplasia
and lymphoma contained a similar number of clones as Myc T-ALL (4.0±2.08 and 2.3±0.57
clones, respectively), but were not able to reliably engraft disease in recipient animals (Table
2). These data suggest that Myc expression, alone, is not sufficient to transform T cells, and
that additional genetic/epigenetic events are required for LPC formation. Interestingly, the
notch1a(ICD) and Myc+ notch1a(ICD) primary T-ALL were comprised of significantly more
subclones than the Myc-induced T-ALL (8.8±2.5 and 6.5±2.1 clones, respectively,
p=0.0001). However, following engraftment into recipient animals, notch1a(ICD) and Myc
+notch1a(ICD) secondary T-ALL contained an average of 3.0±1.3 clones, similar to
transplanted Myc T-ALL (Figure 5A). Given that 2.5×105 cells were transplanted into
recipient animals and that the same clones were present in multiple recipients (n>3 per
tumor) of the same primary T-ALL, the reduced number of subclones following cell
transplantation cannot be accounted for by lack of adequate numbers of transferred LPC
clones but rather suggests that not all Notch-expressing subclones within the primary T-ALL
could reinitiate leukemia growth. Moreover, only 4 of 9 Notch alone-induced leukemias
engrafted disease in recipient animals, even when transplanted with 2.5×106 cells (Table 2),
but exhibited typical lymphoblast morphology (Supplemental Figure 9). These data suggest
that despite GFP-positive cells spreading throughout the primary animals and overtaking
>50% of the body, Notch signaling did not confer a fully transformed phenotype to
thymocytes.
Notch signaling does not increase the frequency of LPCs in T-ALL
Recent data suggests that Notch signaling is critical for LPC maintenance in that Notch
inhibition prevents xenograft growth and can significantly increase T-ALL latency (2,13).
However, it is unclear whether Notch signaling acts to increase the overall frequency of
LPCs in the leukemia; this latter attribute could function in collaboration with Myc to
promote T-ALL onset and enhance the propensity of cells for relapse. Large-scale limiting-
dilution cell transplantation analyses were performed on primary T-ALL to determine the
frequency of LPCs within each leukemia subtype (22 primary and 16 transplanted T-ALL,
n=1,059 transplanted animals). Primary Myc-induced T-ALL had a mean LPC frequency of
1 in 111 cells (95% CI: 1:89–139), while the mean leukemia-propagating cell frequency of
notch1a(ICD) and Myc+notch1a(ICD) leukemias was significantly less, with only 1 in 1,639
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tcells (95% CI: 1:727–3313) and 1 in 1,591 cells (95% CI 1:1088–2477), respectively (Table
3 and Figure 5B, p<0.0001). These data are expected, given that the clonal analysis of
primary leukemias and transplant recipients revealed that a majority of subclones in the Myc
+notch1a(ICD) and notch1a(ICD)-induced T-ALL were not fully transformed LPCs. We
therefore questioned if leukemia-propagating ability was enhanced in LPCs from the Myc
+notch1a(ICD) and notch1a(ICD)-expressing T-ALL following leukemia engraftment, which
would select for the fully transformed clones. GFP-positive T-ALL cells were re-isolated
from transplant recipient animals that received 2.5×105 unsorted primary cells, and then
transplanted at limiting dilution into CG1-strain recipient animals. The mean LPC frequency
of the Myc-induced leukemias did not change following serial transplantation (1 in 74 cells,
95% CI: 1:55–102). However, serially passaged notch1a(ICD) and Myc+notch1a(ICD) T-ALL
exhibited an overall increase in leukemia-propagating ability when compared to the primary
leukemias, with 1 in 205 cells (95% CI: 1:119–354) and 1 in 101 cells (95% CI: 1:75–137)
now capable of initiating leukemia growth, respectively (Table 3 and Figure 5B, p<0.0001).
Despite this overall increase in leukemia-propagating ability, there was no difference in the
LPC frequency between secondary leukemias induced from any combination of transgenes
(p=0.137), indicating that neither Myc nor Notch signaling augments the frequency of LPCs
contained within the leukemia. Myc and Myc+notch1a(ICD)-induced T-ALL expressed both
tal1/lmo2 (Supplemental Figure 11), suggesting that T-ALL molecular subtype differences
are not responsible for modulating LPC activity in our comparsions. Further, tertiary
transplants did not lead to an additional increase in LPC frequency (Supplemental Table 11)
or additional loss of T-ALL subclones.
Discussion
Our work suggests that an important function of Notch signaling in T-ALL development is
to expand a pre-malignant pool of T cell clones, of which a small subset acquire additional
mutations to become fully transformed and capable of leukemia propagation. In this model,
Notch promotes T-ALL progression through clonal expansion. An increase in the number of
pre-malignant cells greatly enhances both the likelihood and speed by which these cells
accumulate the necessary mutations to become fully transformed LPCs. A role for Notch in
the clonal expansion of pre-malignant T cells is in agreement with work from the Kelliher
group, which utilized the Tal1/Lmo2 mouse model of T-ALL to observe that spontaneous
Notch mutation in pre-leukemic animals corresponded to an expansion of DN3/DN4 clones,
which gave rise to T-ALL over time (13). Additional studies from Li et al. showed retroviral
infection of murine lin-hematopoietic precursor cells (HPCs) with NOTCH(ICD) caused a
depletion of B cells and expansion of a CD4+/CD8+ population of T cells that could spread
outside of the thymus, but were non-tumorigenic (14). Similarly, we have found that Notch
signaling caused an expansion of pre-malignant clones that spread outside of the thymus,
and clonal analysis based on TCRβ rearrangements demonstrated that only a small fraction
of these subclones were leukemogenic when introduced into transplant recipient animals,
indicating Notch signaling, alone, is not sufficient to fully transform leukemia propagating
cells. Further, only 4 of 9 primary Notch-induced T-ALL could engraft disease when
transplanted into syngeneic recipient animals after >6 months, while the remaining five
primary T-ALL did not engraft, irrespective of the number of T-ALL cells transplanted
(ranging from 10 to 2.5×106 cells). These data are in agreement with work from Li et al.,
who demonstrated that leukemia-propagating ability arose in Notch(ICD) over-expressing
murine lin-HPCs only after the up-regulation of Akt, Bmi1 and Ras (14), suggesting that the
collaboration of additional oncogenes are required for transformation of Notch expressing
cells. Clappier et al. recently demonstrated that xenograft of primary human T-ALL into
immune-compromised mice selected for a small subset of clones found within the diagnosis
leukemia (5). In Clappier’s elegant experiments, transplantation likely selected for those T-
ALL cells capable of leukemia propagation, and served to identify fully malignant LPCs that
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twere able to drive relapse. Importantly, a large number of clones found in the human
primary leukemia were not detected in either transplanted animals or patients at relapse. In
combination with our results from the zebrafish, these data suggest that clonal expansion of
pre-malignant clones is a common feature of human T-ALL and that a large portion of
genetically distinct clones found within the primary leukemia likely lack self-renewal
potential and cannot remake tumor.
While Notch signaling is likely required for continued tumor growth (2,13,18), we have
found that Notch may not directly promote leukemia-propagating ability. For example,
Notch signaling does not collaborate with Myc to enhance the frequency of leukemia-
propagating cells in T-ALL, and Notch-induced T-ALL do not have higher numbers of
LPCs when compared with T-ALL that expresses Myc alone. These results are in keeping
with data from McCormack et al., who showed that Notch expression in normal thymocytes
does not induce serial repopulating ability or confer self-renewing capability in thymocyte
reconstitution assays. (15). However, our work does not imply that Notch plays no role in
LPC formation. While we have utilized the zebrafish T-ALL model to define the role of
Notch in T-ALL development apart from Myc induction, an important corollary is that Myc
is a critical target of Notch in mammalian T-ALL, and it is possible that Myc expression
plays an important role in the ability of Notch to promote leukemia-propagation in human
disease. For example, Li et al. has suggested that Ras over-expression resulting from
activation of the Notch/Myc pathway axis likely contributes to LPC development in
Notch(ICD) expressing HPCs (14). Further, in a recent study that utilized the TAL1/LMO1
mouse model of T-ALL, spontaneous Notch mutations were found in the Cd3ε+/+ fraction of
T-ALL transplantable cells, but not the Cd3ε−/− fraction, which were unable to engraft
disease in recipient animals (44). The collaboration of Notch, TAL1 and LMO1 was
therefore sufficient to promote LPC formation, which the authors speculate is likely through
the ability of Notch to induce Myc and repress p53. In our work, 100% of Myc-expressing
T-ALL subclones could initiate disease in recipient animals, with ~1% of cells capable of
leukemia- propagation, suggesting the Myc pathway is a potent initiating event in T-ALL.
However, hyperplastic Myc expressing thymocytes that are initially confined to the thymus
are unable to induce disease in transplanted animals, suggesting that Myc alone is also not
sufficient to fully transform thymocytes. Taken together, our data strongly suggests that
additional collaborating genetic events are required along with Notch and/or Myc to elicit
full transformation to thymocytes into T-ALL and subsequently the creation of LPCs.
In addition to identifying an important role of Notch in expanding T-ALL subclones, our
experiments also highlight the use of zebrafish as a powerful model to uncover
evolutionarily conserved pathways involved in T-ALL. For example, our microarray and
cross-species comparisons identified common gene signatures in zebrafish, mouse, and
human T-ALL that are independent of the initiating oncogene, suggesting common
molecular pathways underlie T-ALL development. Mining this data set will likely uncover
important genes regulating T-ALL initiation and progression. Moreover, our microarray
cross-species comparisons revealed a novel Myc signature that is found in a variety of
human and mouse malignancies and identified a unique Notch signature that acts
independent of Myc in T-ALL. For example, we identified hes1 and il7r as Notch target
genes, both of which have been shown to be important Notch targets in human T-ALL and
act independently of Myc (45,46). We also validated potential novel Notch target genes in
human T-ALL cell lines including MYB, MEIS1 and BCL2, which have emerging roles in
T-ALL malignancy but were previously not known to be regulated by Notch (26,47,48).
Future work will determine whether these and other Notch target genes contribute to pre-
malignant thymocyte expansion, altered apoptotic responses, and/or T-ALL proliferation.
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tIn summary, we have utilized the zebrafish mosaic transgenic T-ALL model to determine
that the primary role of Notch signaling is to elicit the expansion of a pool of pre-malignant
thymocytes, increasing the likelihood that a subset of these cells will accumulate the
necessary mutations to become malignant LPCs. Because Notch-induced clonal expansion
occurs even in the presence of Myc over-expression, a model that more accurately mimics
the human condition, we expect that this same cellular mechanism likely drives early clonal
expansion in human T-ALL.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Notch collaborates with Myc to promote T-ALL progression in both stable and mosaic
transgenic zebrafish
(A) Stable transgenic rag2-EGFP-Myc, rag2-NOTCH(ICD)-EGFP, and double transgenic
AB-strain zebrafish were followed for disease onset and photographed at 28, 35, 42 and 49
days of life using epi-fluorescence stereomicroscopy. Alternatively, CG1-strain zebrafish
were injected at the one-cell stage of life with rag2-Myc+rag2-GFP, rag2-
notch1a(ICD)+rag2-GFP, or rag2-Myc+rag2-notch1a(ICD)+rag2-GFP transgenic constructs.
Animals with GFP-labeled thymi were photographed at 28 days of life. Panels are merged
fluorescent and brightfield images. Scale bar, 10 mm. (B) Kaplan Meier analysis of disease
progression in stable transgenic zebrafish. Fish were scored for thymic hyperplasia (left),
lymphoma (middle), or leukemia (right). (C) Kaplan Meier analysis of disease progression
in mosaic transgenic zebrafish. The total number of animals used in each experiments are
shown, and p-values comparing Myc transgenic fish to Myc+Notch(ICD) expressing fish are
denoted in each panel (Log-rank/Mantel-Cox statistic).
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tFigure 2. Characterization of mosaic transgenic zebrafish with Myc-, Notch- and Myc+Notch-
induced T-ALL
(A) May-Grünwald and Wright-Giemsa stained cytospins of kidney marrow from wild-type
and mosaic transgenic zebrafish from each genotype. Scale bar, 20 µm. (B) Real-time RT-
PCR analysis of the T cell-specific genes lck, CD4, CD8 and TCRα, and the B-cell gene
IgM in normal rag2-GFP thymocytes, and GFP-positive T-ALL cells from mosaic
transgenic animals. Data are the average expression from 4 primary T-ALL per group.
Samples were normalized to ef1α expression and gene expression is shown relative to whole
blood cells isolated from normal CG1-strain fish. Error bars are the standard deviation (SD).
(C) Representative FACS analysis of kidney marrow (left) and spleen (right) from wild-type
and mosaic transgenic zebrafish that developed T-ALL. The percentage of lymphocytes,
granulocytes/monocytes, hematopoietic precursors and erythrocytes were quantified by
analysis of cell size and granularity. (D) Real-time RT-PCR analysis of zebrafish myca and
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t(E) mycb expression in normal thymocytes and T-ALL cells. Data are the average of 6
individual primary T-ALL, normalized to ef1α expression and relative to rag2-GFP
thymocytes isolated from 45d animals. Errors bars are +/− SD.
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tFigure 3. Cross-species microarray comparisons identify Myc and Notch signatures in both
human and zebrafish T-ALL
A) Differentially regulated genes found by comparing zebrafish notch1a(ICD)- or Myc+
notch1a(ICD)-induced T-ALL to both Myc-induced T-ALL and normal thymocytes. A subset
of differentially regulated genes is denoted on the left. B) GSEA analysis demonstrate that
Myc and notch1a(ICD) signatures are co-regulated in human T-ALL cells following Notch
inhibition with the SAHM1 stapled peptide. The Myc signature, but not the notch1a(ICD)
gene signature, is coordinately regulated in human mammary epithelial cells (HMECs)
transduced with Myc and in mouse models of Myc-induced B-lymphoma. XBP1-induced
multiple myeloma does not express either the Myc or Notch signature, confirming that our
zebrafish gene signatures are not specific to lymphocytes. The Notch signature is also
negatively associated with B-lymphomas, suggesting a role for Notch in B-cell maturation
or stroma in normal lymph-nodes.
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tFigure 4. Myc+Notch-induced T-ALL have increased cellular turnover in primary, but not
transplanted leukemias
A) EDU staining to quantify the percentage of cells in S-phase of whole blood cells, rag2-
GFP thymocytes, and primary and transplanted T-ALL. Each point is representative of one
sample. (B) AnnexinV staining of apoptotic cells of whole blood cells, rag2-GFP
thymocytes and primary and transplanted T-ALL. Each point represents one sample.
*p=0.0043, Myc compared to Myc+ notch1a(ICD) expressing primary T-ALL. **p=0.0016,
Myc compared Myc+notch1a(ICD)-induced primary T-ALL. NS, not significant comparing
transplanted T-ALL.
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tFigure 5. Notch expands a pool of pre-malignant clones but does not enhance the frequency of
LPCs within the leukemia
(A) A PCR based assay to detect TCRβ rearrangements was used to determine the number
of T-cell clones that comprise the primary and transplanted T-ALL. *p<0.0001, comparing
primary Myc- and Myc+notch1a(ICD)-induced T-ALL,**p<0.0001, comparing Myc and
notch1a(ICD)-expressing T-ALL, NS not significant, comparing transplanted T-ALL. (B)
Extreme Limiting Dilution Analysis (ELDA) statistical software was used to calculate the
LPC frequency within Myc-, notch1a(ICD)- and Myc+notch1a(ICD)-induced primary and
transplanted T-ALL. Each point represents the average LPC frequency of one T-ALL. The
raw data are presented in Table 1 (n=1,059 transplant animals). #p<0.0001, comparing
primary Myc and Myc+notch1a(ICD)-induced T-ALL, ##p<0.0001, comparing Myc and
Myc+notch1a(ICD)-induced T-ALL, NS not significant, comparing transplanted T-ALL.
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